Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38

Inclusion Criteria: * Patients who have been diagnosed, by histologic and clinical examination, with resected AJCC stage I or II melanoma. * Patients who have any evidence of metastasis will not be eligible. * All patients must have: 1. Karnofsky performance of 80% or higher 2. ECOG performance status of 0 or 1 3. Ability and willingness to give informed consent * Laboratory parameters as follows: 1. ANC: 90% of lower limit of normal (LLN) to 120% of upper limit of normal (ULN) 2. Platelets: 100-500 x 103/uL 3. Hgb: 90% LLN to 120% ULN 4. Hepatic: 1. AST, ALT, Bilirubin, and Alk phos within normal limits, 2. LDH up to 1.2 x ULN 5. Renal: 1. Creatinine up to 1.5 x ULN * Age 18-85 years at the time of study entry. Exclusion Criteria: * Patients who are currently receiving cytotoxic chemotherapy, interferon, or radiation or who have received this therapy within the preceding 12 weeks. * Patients with known or suspected allergies to any component of the vaccine. * Patients receiving the following medications at study entry or within the preceding 4 weeks are excluded: * Agents with putative immunomodulating activity (with the exception of non-steroidal anti-inflammatory agents), * Allergy desensitization injections, * Corticosteroids, administered parenterally or orally. Topical corticosteroids are acceptable. * Any growth factors, Interleukin-2 or other interleukins. * Pregnancy or the possibility of becoming pregnant during vaccine administration. Female patients of child-bearing potential must have a negative pregnancy test (urinary or serum beta-HCG) prior to administration of the injection. * Patients in whom there is a medical contraindication or potential problem in complying with the requirements of the protocol, in the opinion of the investigator. * Patients classified according to the New York Heart Association classification as having Class III or IV heart disease. * Patients with serious symptomatic active pulmonary disease, with pleural effusions, or with a history of pulmonary edema. * Patients who have systemic autoimmune disease with visceral involvement. * Patients with clinically apparent skin infection or other clinically evident inflammation involving the skin adjacent to the melanoma biopsy scar.